Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection

The objective of the study is to compare the effect of adding 2 oral hepatitis C virus (HCV)
protease inhibitors, telaprevir versus boceprevir, as part of current standard treatment
regimen with (pegylated-interferon-alpha + ribavirin) for HCV Genotype-1 infection. Data
will be obtained from medical records of consenting patients.

Inclusion Criteria:

- Age - 18-64 years

- HCV genotype 1

- HCV RNA >100,000

- Liver biopsy within 5 years before enrollment

- Absolute neutrophil count of at least 1200 per cubic millimeter

- Platelet count of at least 90,000 per cubic millimeter

- Hemoglobin level of at least 12 g per deciliter

- Signed informed consent and Health Insurance Portability and Accountability Act
(HIPAA) forms

Exclusion Criteria:

- HCV genotypes other than genotype 1

- Immunocompromised conditions including HIV, transplant or immunosuppressive drugs

- Decompensated liver disease or hepatocellular carcinoma

- Any other types of active cancer

- Active autoimmune disorders

- Major psychiatric disorders

- Active drug or alcohol use

- Pregnancy or lactation

- Patients with allergy to any of the drugs used in this study

- Drugs that may interact with boceprevir or telaprevir as listed in the package insert